kidneys, adrenal glands

While its investigational regimen fell short of the primary efficacy endpoint, AVEO dug into data from its control group and touted a “clinically meaningful” improvement in progression-free survival in patients receiving Fotivda monotherapy.

After nixing a twice-daily version of its oral GLP-1 agonist, Pfizer is hoping to break into the weight-loss space with a once-daily version, but experts question its outlook.

4D Molecular Therapeutics revealed positive Phase II data Wednesday for its wet age-related macular degeneration candidate at the American Society of Retina Specialists (ASRS) annual scientific meeting.

After completing a buyout transaction with The Column Group to remove it from the stock exchange, NGM Bio has raised a $122M Series A to fund a registrational study for a rare liver disease drug and a Phase II trial in hyperemesis gravidarum.


Roche said on Wednesday a second drug candidate from its purchase of Carmot Therapeutics yielded positive results in an early-stage trial, as the Swiss drugmaker asserted itself as a late contender in the race to develop obesity drugs.

Novo Nordisk

Swiss biotech company Asceneuron said on Tuesday it had raised $100 million from investors including the controlling shareholder of Wegovy maker Novo Nordisk to fund clinical development of its Alzheimer’s disease drug.

Yesterday Amylyx Pharmaceuticals announced it has acquired a glucagon-like peptide-1 receptor antagonist, avexitide, from Eiger BioPharmaceuticals that is ready for Phase III trials and has been granted FDA Breakthrough Therapy Designation for post-bariatric hypoglycemia and congenital hyperinsulinism.


Yesterday the company terminated the development of its investigational bispecific T-cell engager AMG 794, which it had been studying in a Phase I trial for several solid tumors including non-small cell lung cancer and epithelial ovarian cancer.

Pfizer logo

“After more than 15 years as the architect of Pfizer’s exceptional scientific and research and development resurgence, Mikael and I recently discussed starting the process to look for his successor,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer.

With the antibody drug conjugate market projected to hit $28 billion by 2028, some companies are looking to harness the drugs for immunotherapy.